📊 Score Breakdown
Offering Ability
40
Cash Runway
0
Float Risk
55
Warrant Exposure
30
Convertible Debt—
🌦️ Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
35%
🔁 Convertible Conversion
40%
• Significant convertible debt: 16% potential dilution
• Elevated convertible risk (60/100)
📉 Score Deterioration
40%
• Score rose 16 points recently (worsening)
💰 Capital Raise
18%
• Active ATM program with $75M remaining capacity
💹 Market Data
Market Cap$187.37M
Shares Outstanding16.96M
Float9.69M
Cash$50.75M
Debt$13.65M
Short InterestN/A
🏛 Institutional Holdings
QoQ: ↓ 4.7% shares (2025Q4 vs prior)
53 institutional holders · 8.07M shares
#1
ORBIMED ADVISORS LLC
2.25M shares
#2
Atlas Venture Life Science Advisors, LLC
2.09M shares
#3
Carlyle Group Inc.
1.10M shares
+ 17 more holders Sign up free to view →
📉 Short Interest
Short Interest632.7K
Days to Cover2.7
% of Float6.5%
FINRA data as of May 15, 2026
📁 Recent SEC Activity
xbrl
XBRL CONVERTIBLE
Dec 31, 2024
424B5
ATM
Apr 24, 2026
8-K
8K EVENT
Apr 24, 2026
424B5
ATM
Mar 27, 2026
8-K
8K EVENT
Mar 27, 2026
Full SEC filing analysis available with free account →
📰 Recent News
No recent news
🔬 More Research for QTTB
📊 QTTB FDA Catalyst Timeline & Biotech Grade — BiotechSigns
📡 QTTB Signal Convergence & Dark Pool Activity — StonkWhisper
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.